Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas
Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · 698-705.e1
DOI: 10.1016/j.clml.2026.07.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Jonathan A Baron und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, B-Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lymphoma Research Foundation.
Abstract (Originalsprache)
INTRODUCTION/BACKGROUND: T-cell-engaging bispecific antibodies (BsAbs) are effective for relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). Radiation therapy (RT) is increasingly used for palliation or bridging/cytoreduction in patients receiving BsAbs, but data on the safety of RT delivered in close temporal proximity to BsAbs are limited. We report the largest series to date evaluating RT and BsAbs in B-NHL. PATIENTS AND METHODS: We retrospectively identified patients with B-NHL who received RT ≤ 3 months before, during, or ≤ 3 months after BsAb at a single institution between 2018 and 2024. Timing was categorized as pre-, peri-, or post-BsAb. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per ASTCT criteria; other toxicities per CTCAE v5.0. In-field responses were assessed per Lugano criteria. RESULTS: Twenty-nine patients underwent 31 BsAb courses and received RT to 52 sites (50% pre-, 13% peri-, 37% post-BsAb). Common histologies included DLBCL (52%), follicular lymphoma (FL) (26%), and transformed FL (16%). All RT-related toxicities were grade 1 to 2, with no RT-related hospitalizations. CRS occurred in 7 BsAb courses and ICANS in 4, with no apparent relationship to RT timing or dose. Early post-RT lymphopenia was common across groups, but its frequency and severity did not differ by RT timing. Among 44 evaluable lesions, the in-field overall response rate was 84% (CR 45%, PR 39%). CONCLUSION: RT before, during, or after BsAb was well tolerated, without apparent additive toxicity, and achieved high in-field response rates, supporting the safe integration of RT with BsAbs for R/R B-NHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA.
- Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
- Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
- Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address: elise.chong@…
- Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA. Electronic address: harper.hubbeling@pennmedicine.upenn.edu.
Förderung
- Lymphoma Research Foundation
Zitieren
APA
Baron, J. A., Chelius, M., Singh, G., Schad, M. D., Berger, M., Chong, E. R., Thomas, C. J., Carter, J. S., Cook, M. R., Nasta, S. D., Landsburg, D. J., Barta, S. K., Svoboda, J., Schuster, S. J., Yegya-Raman, N., LaRiviere, M. J., Plastaras, J. P., Chong, E. A., & Hubbeling, H. (2026). Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia, 26(10), 698-705.e1. https://doi.org/10.1016/j.clml.2026.07.004
Vancouver
Baron JA, Chelius M, Singh G, Schad MD, Berger M, Chong ER, et al. Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):698-705.e1. doi:10.1016/j.clml.2026.07.004
BibTeX
@article{Baron2026,
author = {Baron, Jonathan A and Chelius, Monica and Singh, Gurbani and Schad, Michael D and Berger, Melanie and Chong, Emeline R and Thomas, Colin J and Carter, Jordan S and Cook, Michael R and Nasta, Sunita D and Landsburg, Daniel J and Barta, Stefan K and Svoboda, Jakub and Schuster, Stephen J and Yegya-Raman, Nikhil and LaRiviere, Michael J and Plastaras, John P and Chong, Elise A and Hubbeling, Harper},
title = {Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {10},
pages = {698--705.e1},
doi = {10.1016/j.clml.2026.07.004}
}
EUVIMED